Table 2

Clinical outcome of patients treated with sirolimus

Case No	Snellen visual acuity pretreatment	Snellen visual acuity post-treatment	Intraocular inflammation BIO score RE/LE pretreatment	Intraocular inflammation BIO score RE/LE post-treatment	Pretreatment prednisolone dose/current prednisolone dose	Clinical outcome
BIO, binocular indirect score; CMO, cystoid macular oedema; HM, hand movements; IV MP, intravenous methylprednisolone.
1	6/6, 6/9	6/5+3, 6/6+3	0 1	1 2	40 mg/10 mg	Treatment failure
1	6/6, 6/9	6/5+3, 6/6+3	0 1	1 2	40 mg/10 mg	Initial control of inflammation followed by relapse on tapering treatment requiring higher doses of sirolimus with intolerable side effects
						Current medication: tacrolimus, prednisolone and sirolimus
2	6/18, 6/12	6/9, 6/9	3 3	0 0	40 mg/6 mg	Symptom improvement: reduction of floaters
3	6/36, 6/4	6/36, 6/4	1 0	0 0	Intermittent IV MP/0 mg	Symptom improvement: reduction in pain and photophobia
4	6/6+1, 6/12	6/5−1, 6/9	1 1	0 0	30 mg/0 mg	Reduction in vasculitis and regression of neovascularisation
5	1/60, 6/18	1/60, 6/9	1 2	0 0	40 mg/15 mg	Treatment failure
						Despite reduction of inflammation mild CMO persists. Treatment withdrawn due to side effects
						Current medication: tacrolimus and oral corticosteroids
6	6/5, 6/9	6/5, 6/5	0 2	0 0	50 mg reducing to 20 mg/0 mg	Symptom improvement: reduction in pain
						Regression of vasculitis with no further flare ups
7	6/18, HM	6/18, HM	0 0	0 0	15 mg/7.5 mg	Marked improvement in systemic symptoms of Behçet’s syndrome
						Regression of vasculitis with no further flare ups
8	HM, 6/12	HM, 6/12	2 2	1 1	Intermittent IV MP/6 mg and pulsed IV MP	Treatment failure
8	HM, 6/12	HM, 6/12	2 2	1 1	Intermittent IV MP/6 mg and pulsed IV MP	Continuing episodes of vasculitis leading to transient vision loss requiring repeated IV MP
						Currently on tacrolimus, prednisolone, and sirolimus